FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2013035959> ?p ?o ?g. }

• W2013035959 endingPage "e6358" @default.
• W2013035959 startingPage "e6358" @default.
• W2013035959 abstract "The fixed dose antimalarial combination of dihydroartemisinin-piperaquine (DP) is a promising new artemisinin-based combination therapy (ACT). We present an individual patient data analysis of efficacy and tolerability in acute uncomplicated falciparum malaria, from seven published randomized clinical trials conducted in Africa and South East Asia using a predefined in-vivo protocol. Comparator drugs were mefloquine-artesunate (MAS3) in Thailand, Myanmar, Laos and Cambodia; artemether-lumefantrine in Uganda; and amodiaquine+sulfadoxine-pyrimethamine and artesunate+amodiaquine in Rwanda.In total 3,547 patients were enrolled: 1,814 patients (32% children under five years) received DP and 1,733 received a comparator antimalarial at 12 different sites and were followed for 28-63 days. There was no significant heterogeneity between trials. DP was well tolerated with 1.7% early vomiting. There were less adverse events with DP in children and adults compared to MAS3 except for diarrhea; ORs (95%CI) 2.74 (2.13 to 3.51) and 3.11 (2.31 to 4.18), respectively. DP treatment resulted in a rapid clearance of fever and parasitaemia. The PCR genotype corrected efficacy at Day 28 of DP assessed by survival analysis was 98.7% (95%CI 97.6-99.8). DP was superior to the comparator drugs in protecting against both P.falciparum recurrence and recrudescence (P = 0.001, weighted by site). There was no difference between DP and MAS3 in treating P. vivax co-infections and in suppressing the first relapse (median interval to P. vivax recurrence: 6 weeks). Children under 5 y were at higher risk of recurrence for both infections. The proportion of patients developing gametocytaemia (P = 0.002, weighted by site) and the subsequent gametocyte carriage rates were higher with DP (11/1000 person gametocyte week, PGW) than MAS3 (6/1000 PGW, P = 0.001, weighted by site).DP proved a safe, well tolerated, and highly effective treatment of P.falciparum malaria in Asia and Africa, but the effect on gametocyte carriage was inferior to that of MAS3." @default.
• W2013035959 created "2016-06-24" @default.
• W2013035959 creator A5013453998 @default.
• W2013035959 creator A5028227666 @default.
• W2013035959 creator A5031555005 @default.
• W2013035959 creator A5033754121 @default.
• W2013035959 creator A5033897984 @default.
• W2013035959 creator A5049294699 @default.
• W2013035959 creator A5054759230 @default.
• W2013035959 creator A5060343662 @default.
• W2013035959 creator A5063691650 @default.
• W2013035959 creator A5068881280 @default.
• W2013035959 creator A5078711287 @default.
• W2013035959 creator A5083740562 @default.
• W2013035959 creator A5084217335 @default.
• W2013035959 date "2009-07-29" @default.
• W2013035959 modified "2023-10-18" @default.
• W2013035959 title "Safety and Efficacy of Dihydroartemisinin-Piperaquine in Falciparum Malaria: A Prospective Multi-Centre Individual Patient Data Analysis" @default.
• W2013035959 cites W1483203554 @default.
• W2013035959 cites W1595974425 @default.
• W2013035959 cites W1912267960 @default.
• W2013035959 cites W1970461627 @default.
• W2013035959 cites W1970856471 @default.
• W2013035959 cites W1975267889 @default.
• W2013035959 cites W1982011978 @default.
• W2013035959 cites W2023687237 @default.
• W2013035959 cites W2033890227 @default.
• W2013035959 cites W2052262611 @default.
• W2013035959 cites W2061999977 @default.
• W2013035959 cites W2062087372 @default.
• W2013035959 cites W2112719929 @default.
• W2013035959 cites W2115398829 @default.
• W2013035959 cites W2118288290 @default.
• W2013035959 cites W2123129595 @default.
• W2013035959 cites W2124740902 @default.
• W2013035959 cites W2125435699 @default.
• W2013035959 cites W2130028379 @default.
• W2013035959 cites W2134055441 @default.
• W2013035959 cites W2147783946 @default.
• W2013035959 cites W2149109668 @default.
• W2013035959 cites W2149251475 @default.
• W2013035959 cites W2150330391 @default.
• W2013035959 cites W2161141025 @default.
• W2013035959 cites W2161917102 @default.
• W2013035959 cites W2301023468 @default.
• W2013035959 doi "https://doi.org/10.1371/journal.pone.0006358" @default.
• W2013035959 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2716525" @default.
• W2013035959 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19649267" @default.
• W2013035959 hasPublicationYear "2009" @default.
• W2013035959 type Work @default.
• W2013035959 sameAs 2013035959 @default.
• W2013035959 citedByCount "96" @default.
• W2013035959 countsByYear W20130359592012 @default.
• W2013035959 countsByYear W20130359592013 @default.
• W2013035959 countsByYear W20130359592014 @default.
• W2013035959 countsByYear W20130359592015 @default.
• W2013035959 countsByYear W20130359592016 @default.
• W2013035959 countsByYear W20130359592017 @default.
• W2013035959 countsByYear W20130359592018 @default.
• W2013035959 countsByYear W20130359592019 @default.
• W2013035959 countsByYear W20130359592020 @default.
• W2013035959 countsByYear W20130359592021 @default.
• W2013035959 countsByYear W20130359592022 @default.
• W2013035959 countsByYear W20130359592023 @default.
• W2013035959 crossrefType "journal-article" @default.
• W2013035959 hasAuthorship W2013035959A5013453998 @default.
• W2013035959 hasAuthorship W2013035959A5028227666 @default.
• W2013035959 hasAuthorship W2013035959A5031555005 @default.
• W2013035959 hasAuthorship W2013035959A5033754121 @default.
• W2013035959 hasAuthorship W2013035959A5033897984 @default.
• W2013035959 hasAuthorship W2013035959A5049294699 @default.
• W2013035959 hasAuthorship W2013035959A5054759230 @default.
• W2013035959 hasAuthorship W2013035959A5060343662 @default.
• W2013035959 hasAuthorship W2013035959A5063691650 @default.
• W2013035959 hasAuthorship W2013035959A5068881280 @default.
• W2013035959 hasAuthorship W2013035959A5078711287 @default.
• W2013035959 hasAuthorship W2013035959A5083740562 @default.
• W2013035959 hasAuthorship W2013035959A5084217335 @default.
• W2013035959 hasBestOaLocation W20130359591 @default.
• W2013035959 hasConcept C126322002 @default.
• W2013035959 hasConcept C197934379 @default.
• W2013035959 hasConcept C203014093 @default.
• W2013035959 hasConcept C2776120307 @default.
• W2013035959 hasConcept C2776992834 @default.
• W2013035959 hasConcept C2777199930 @default.
• W2013035959 hasConcept C2777616469 @default.
• W2013035959 hasConcept C2778048844 @default.
• W2013035959 hasConcept C2778059366 @default.
• W2013035959 hasConcept C2778371730 @default.
• W2013035959 hasConcept C2778375690 @default.
• W2013035959 hasConcept C2778629330 @default.
• W2013035959 hasConcept C2781160685 @default.
• W2013035959 hasConcept C71924100 @default.
• W2013035959 hasConcept C90924648 @default.
• W2013035959 hasConcept C98274493 @default.
• W2013035959 hasConceptScore W2013035959C126322002 @default.
• W2013035959 hasConceptScore W2013035959C197934379 @default.
• W2013035959 hasConceptScore W2013035959C203014093 @default.

• next